Patents by Inventor Nathalie Marie-Josephe Claude Garcon

Nathalie Marie-Josephe Claude Garcon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccine composition containing adjuvants
    Patent number: 7147862
    Abstract: The present invention provides vaccine compositions comprising 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccines compositions are potent inducers of CTL and ? IFN responses.
    Type: Grant
    Filed: August 12, 1997
    Date of Patent: December 12, 2006
    Assignee: SmithKline Beecham Biologicals (S.A.)
    Inventors: Jean-Paul Prieels, Nathalie Marie-Josephe Claude Garcon-Johnson, Moncef Slaoui, Pietro Pala
  • Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid A
    Patent number: 6893644
    Abstract: A vaccine formulation for the treatment or prophylaxis of hepatitis, especially hepatitis, especially hepatitis B, infections is provided comprising the hepatitis antigen and a suitable carrier such as alum in combination with 3-O-deacylated monophosphoryl lipid. A combination vaccines including the vaccine formulation are also described.
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: May 17, 2005
    Assignee: SmithKline Beecham Biologicals s.a.
    Inventors: Nathalie Marie-Josephe Claude Garcon-Johnson, Pierre Hauser, Clothilde Thiriart, Pierre Voet
  • Vaccines containing a saponin and a sterol
    Patent number: 6846489
    Abstract: A novel adjuvant composition comprising a sterol (e.g., cholesterol, ?-sitosterol, stigmasterol, ergosterol, and ergocalciferol) and saponin fraction (e.g., QS21, also known as QA21) in the form of an immunostimulating complex, or ISCOM, is disclosed. QS21 is an immunologically active saponin fraction having adjuvant activity derived from the bark of Quillaja Saponaria Molina. Previous attempts in the prior art to prepare ISCOMs comprising QS21 were unsuccessful. Thus, the instant application discloses the first successful attempt to prepare ISCOMs comprising purified QS21. Small unilamelar liposomes containing cholesterol, in the absence of any detergent, were prepared, followed by the addition of an aqueous solution of QS21. The claimed compositions will prove useful in the preparation of highly immunogenic vaccine compositions.
    Type: Grant
    Filed: January 6, 2000
    Date of Patent: January 25, 2005
    Assignee: SmithKline Beecham Biologicals s.a.
    Inventors: Nathalie Marie-Josephe Claude Garcon, Martin Friede
  • Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
    Patent number: 6620414
    Abstract: A vaccine formulation for the treatment or prophylaxis of hepatitis, especially hepatitis B, infections is provided comprising the hepatitis antigen and a suitable carrier such as alum in combination with 3-O-deacylated monophosphoryl lipid A. Combination vaccines including the vaccine formulation are also described.
    Type: Grant
    Filed: August 21, 2001
    Date of Patent: September 16, 2003
    Assignee: SmithKline Beecham Biologicals (s.a.)
    Inventors: Nathalie Marie-Josephe Claude Garcon-Johnson, Pierre Hauser, Clothilde Thiriart, Pierre Voet
  • HEPATITIS B VACCINE
    Publication number: 20020192224
    Abstract: A novel vaccine formulation is provided, comprising a hepatitis B component, particularly hepatitis B surface antigen, in combination with aluminum phosphate and 3 de-O-acylated monophosphoryl lipid A.
    Type: Application
    Filed: December 6, 2000
    Publication date: December 19, 2002
    Applicant: SmithKline Beecham Biologicals, s.a.
    Inventors: Pierre Hauser, Nathalie Marie-Josephe Claude Garcon, Pierre Desmons
  • Hepatitis B vaccine
    Patent number: 6488934
    Abstract: A novel vaccine formulation is provided, comprising a hepatitis B component, particularly hepatitis B surface antigen, in combination with aluminum phosphate and 3 de-O-acylated monophosphoryl lipid A.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: December 3, 2002
    Assignee: SmithKline Beecham Biologicals S.A.
    Inventors: Pierre Hauser, Nathalie Marie-Josephe Claude Garcon, Pierre Desmons
  • Epatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
    Publication number: 20020028209
    Abstract: A vaccine formulation for the treatment or prophylaxis of hepatitis, especially hepatitis B, infections is provided comprising the hepatitis antigen and a suitable carrier such as alum in combination with 3-O-deacylated monophosphoryl lipid A. Combination vaccines including the vaccine formulation are also described.
    Type: Application
    Filed: August 21, 2001
    Publication date: March 7, 2002
    Applicant: SmithKline Beecham Biologicals sa
    Inventors: Nathalie Marie-Josephe Claude Garcon-Johnson, Pierre Hauser, Clothilde Thiriart, Pierre Voet
  • Herpes simplex vaccine comprising HSV glycoprotein GD and 3 deacylated monophosphoryl lipid A
    Patent number: 6027730
    Abstract: Novel herpes simplex (HSV) vaccine formulations are provided. These comprise HSV glycoprotein gD or immunological fragments in conjunction with 3 Deacylated monophosphoryl lipid A.
    Type: Grant
    Filed: September 9, 1994
    Date of Patent: February 22, 2000
    Assignee: Smithkline Beecham Biologicals
    Inventors: Myriam Francotte, Jean-Paul Prieels, Moncef Slaoui, Nathalie Marie-Josephe Claude Garcon-Johnson
  • Hepatitis B vaccine
    Patent number: 5972346
    Abstract: A novel vaccine formulation is provided, comprising a hepatitis B component, particularly hepatitis B surface antigen, in combination with aluminum phosphate and 3-O-acylated monophosphoryl lipid A.
    Type: Grant
    Filed: October 27, 1997
    Date of Patent: October 26, 1999
    Assignee: SmithKline Beecham Biologicals S.A.
    Inventors: Pierre Hauser, Nathalie Marie-Josephe Claude Garcon, Pierre Desmons
  • Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
    Patent number: 5776468
    Abstract: Novel vaccine compositions comprising small particles of 3-O-deacylated monophosphoryl lipid A are provided. In particular the particle size is below 120 nm. Such vaccine compositions have superior immunological properties.
    Type: Grant
    Filed: February 12, 1996
    Date of Patent: July 7, 1998
    Assignee: SmithKline Beecham Biologicals (S.A.)
    Inventors: Pierre Hauser, Pierre Voet, Moncef Slaoui, Nathalie Marie-Josephe Claude Garcon-Johnson, Pierre Desmons
  • Vaccine composition containing adjuvants
    Patent number: 5750110
    Abstract: The present invention provides vaccine compositions comprising 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccines compositions are potent inducers of CTL and .gamma. IFN responses.
    Type: Grant
    Filed: February 17, 1995
    Date of Patent: May 12, 1998
    Assignee: SmithKline Beecham Biologicals, s.a
    Inventors: John Paul Prieels, Nathalie Marie-Josephe Claude Garcon-Johnson, Moncef Slaoui, Pietro Pala